A Dose Escalation Study of SCB01A in Subjects With Advanced Solid Tumors Who Have Failed Standard Therapy

NCT ID: NCT01159522

Last Updated: 2017-10-19

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 33 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-04-30
• Study Completion Date: 2017-07-11

Brief Summary

The goal of this study with SCB01A is to determine the Maximum Tolerated Dose of SCB01A in patients with advanced solid tumors that have failed previous therapy.

Detailed Description

This is an open-label, single-arm, dose-escalation, safety and tolerability study. Eligible subjects will be assigned to a SCB01A dose level at the time of study entry and scheduled to receive two treatment cycles with SCB01A for the observation of DLT. A treatment cycle is defined as a three-hour infusion of SCB01A given every 21 days. Unless any off-study criteria are met, the study period of each subject can be up to two cycles.

Conditions

Solid Tumors

Keywords

Advanced Solid Tumors Who Have Failed Standard Therapy

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

SCB01A

This is an open-label, single-arm, dose-escalation, safety and tolerability study. Eligible subjects will be assigned to a SCB01A dose level at the time of study entry and scheduled to receive two treatment cycles with SCB01A for the observation of DLT. A treatment cycle is defined as a three-hour infusion of SCB01A given every 21 days. Unless any off-study criteria are met, the study period of each subject can be up to two cycles.

Group Type: EXPERIMENTAL

SCB01A

Intervention Type: DRUG

This is an open-label, single-arm, dose-escalation, safety and tolerability study. Eligible subjects will be assigned to a SCB01A dose level at the time of study entry and scheduled to receive two treatment cycles with SCB01A for the observation of DLT. A treatment cycle is defined as a three-hour infusion of SCB01A given every 21 days. Unless any off-study criteria are met, the study period of each subject can be up to two cycles.

Interventions

SCB01A

This is an open-label, single-arm, dose-escalation, safety and tolerability study. Eligible subjects will be assigned to a SCB01A dose level at the time of study entry and scheduled to receive two treatment cycles with SCB01A for the observation of DLT. A treatment cycle is defined as a three-hour infusion of SCB01A given every 21 days. Unless any off-study criteria are met, the study period of each subject can be up to two cycles.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Subjects who are at least 18 years of age.

2. Have provided written informed consent prior to the initiation of study procedures.

3. Have histologically or cytologically confirmed diagnosis of an advanced solid tumor that has failed to respond to all available standard treatments.

4. Have ECOG PS scale of 0-1 at the time of enrollment.

5. Have adequate organ function:

1. Bone marrow function:

• White blood cell count (WBC) ≥ 4000/μL
• Absolute neutrophil count (ANC) ≥ 1500/μL
• Hemoglobin ≥ 10.0 g/dL
• Platelet count ≥ 100,000/μL

2. Hepatic Function:

• Serum total bilirubin level ≤ 1.0 x upper normal limit
• Serum alanine aminotransferase (ALT) level ≤ 2.5 x upper normal limit

3. Renal Function:

• Serum creatinine ≤ 1.0 x upper normal limit and creatinine clearance (estimated by Cockcroft-Gault formula) > 60 mL/min

4. Heart Function:

• Ejection fraction ≥ 55%
• QTC < 450 msec

6. Have a life expectancy of at least 3 months

7. Have negative serum pregnancy test within 1 week before study drug administration (for women of childbearing potential and not diagnosed as germ cell tumor with beta-HCG only).

8. Are willing to practice medically accepted contraception (if the risk of contraception exists) throughout the study period (from screening until Final Visit).

Exclusion Criteria

1. Subjects who have failed to recover from prior anti-cancer treatment-related toxicities, e.g. surgery, chemotherapy, radiotherapy, target therapy, biologic therapy, immunotherapy, alternative medicine, hormonal therapy, or investigational agent(s).

2. Treatment with an investigational drug, chemotherapy, targeting agent(s), biologic therapy (e.g., IL-2, Interferon, etc.), immunotherapy (e.g. tumor vaccine, etc.), alternative medicine or hormonal therapy (e.g. anti-estrogens, anti-androgens, etc.), radiation (except to bone) or surgery (except exploratory biopsy or intravenous device implantation, etc.) within 28 days prior to study entry.

3. Grade 2 or higher sensory neuropathy of any etiology.

4. Subjects with severe cardiopulmonary diseases (including history of stable, effort-induced or unstable angina pectoris, myocardial infarction, or arrhythmia) or other systemic diseases under poor control.

5. Females who are pregnant, lactating, or have a positive serum pregnancy test except those are diagnosed as germ cell tumor with beta-HCG prior to study treatment. Pre-menopausal women who are not abstinent must prove surgical sterility or compliance with a contraceptive regimen. Male subjects and male partners of female subjects must be abstinent, surgically sterile, or utilizing a barrier contraceptive method.

6. Tumor with central nervous system (CNS) involvement.

7. Subjects with concomitant active 2nd primary malignancies or disease-free for no more than 3 years following a definitive therapy for prior metachronous malignancies, except for surgically cured carcinoma, i.e. in situ of the cervix or adequately treated basal cell carcinoma of the skin or Dukes' A colorectal cancer.

8. Known history of allergy to any component of this investigational preparation.

9. History of exposure to SCB01A or its analogs.

10. Active infection requiring antibiotic therapy at time of study entry.

11. Is unwilling or unable to comply with the protocol requirements.

12. Known human immunodeficiency virus (HIV) infection.

13. History of receiving organ transplantation or immunologic illness that require continuous immunosuppressant agent therapy.

14. Have other medical or psychological conditions that would not permit the study participant to complete the study or sign informed consent.

15. Have any other disease, dysfunction, alcohol or drug abuse, physical examination or lab finding that, in the investigator's opinion, would exclude the subject from the study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

SynCore Biotechnology Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Muh-Hwan Su, Ph.D.

Role: STUDY_DIRECTOR

SynCore Biotechnology

Locations

National Cheng Kung University Hospital

Tainan City, , Taiwan

National Taiwan University Hospital

Taipei, , Taiwan

Taipei Medical University Hospital

Taipei, , Taiwan

Countries

Taiwan

References

Shiah HS, Chiang NJ, Lin CC, Yen CJ, Tsai HJ, Wu SY, Su WC, Chang KY, Wang CC, Chang JY, Chen LT. Phase I Dose-Escalation Study of SCB01A, a Microtubule Inhibitor with Vascular Disrupting Activity, in Patients with Advanced Solid Tumors. Oncologist. 2021 Apr;26(4):e567-e579. doi: 10.1002/onco.13612. Epub 2020 Dec 18.

Reference Type: DERIVED

PMID: 33245172 (View on PubMed)

Other Identifiers

SCB01A-01

Identifier Type: -

Identifier Source: org_study_id